Subscribe To
Catalyst (cprx) skyrockets 110% over a year: here's why
Catalyst's (CPRX) stock price has more than doubled in the past year, driven by its sole marketed drug, Firdapse, approved for the treatment of Lamber...
March 10, 2022, 12:47 pm
Intra-cellular; long-term to own with a few fda approvals and ability to expand
CAPLYTA has been approved by the FDA for the treatment of adults with schizophrenia and ...
March 8, 2022, 3:09 pm
Why alpine immune's shares are falling today
The FDA has placed a partial clinical hold on Alpine Immune Sciences Inc's (NASDAQ: ALPN) NEON-2 trial evaluating davoceticept (ALPN-202) in combi...
March 7, 2022, 12:13 pm
Why alpine immune's shares are falling today
The FDA has placed a partial clinical hold on Alpine Immune Sciences Inc's (NASDAQ: ALPN) NEON-2 trial evaluating davoceticept (ALPN-202) in combi...
March 7, 2022, 12:13 pm
Why alpine immune's shares are falling today
The FDA has placed a partial clinical hold on Alpine Immune Sciences Inc's (NASDAQ: ALPN) NEON-2 trial evaluating davoceticept (ALPN-202) in combi...
March 7, 2022, 12:13 pm
What to expect from urban outfitters' stock post q4?
Urban Outfitters, a lifestyle retailer focusing on young adults and teenagers, is scheduled to report i...
February 28, 2022, 2:00 pm
What to expect from urban outfitters' stock post q4?
Urban Outfitters, a lifestyle retailer focusing on young adults and teenagers, is scheduled to report i...
February 28, 2022, 2:00 pm
What to expect from urban outfitters' stock post q4?
Urban Outfitters, a lifestyle retailer focusing on young adults and teenagers, is scheduled to report i...
February 28, 2022, 2:00 pm
Moderna's stock gains 3% as it moves forward with phase 3 clinical trial for rsv vaccine candidate
Shares of Moderna Inc. MRNA, +2.82% gained 3.0% in trading on Monday after the company said it began a Phase 3 clinical trial evaluating its respirato...
February 22, 2022, 10:30 am
Moderna's stock gains 3% as it moves forward with phase 3 clinical trial for rsv vaccine candidate
Shares of Moderna Inc. MRNA, +2.82% gained 3.0% in trading on Monday after the company said it began a Phase 3 clinical trial evaluating its respirato...
February 22, 2022, 10:30 am
Moderna's stock gains 3% as it moves forward with phase 3 clinical trial for rsv vaccine candidate
Shares of Moderna Inc. MRNA, +2.82% gained 3.0% in trading on Monday after the company said it began a Phase 3 clinical trial evaluating its respirato...
February 22, 2022, 10:30 am
Fda approves agios' mitapivat as first disease-modifying therapy for genetic blood disorder
The FDA approved Agios Pharmaceuticals Inc's (NASDAQ: AGIO) Pyrukynd (mitapivat) for hemolytic anemia in ad...
February 18, 2022, 5:41 am
Fda approves agios' mitapivat as first disease-modifying therapy for genetic blood disorder
The FDA approved Agios Pharmaceuticals Inc's (NASDAQ: AGIO) Pyrukynd (mitapivat) for hemolytic anemia in ad...
February 18, 2022, 5:41 am
Fda approves agios' mitapivat as first disease-modifying therapy for genetic blood disorder
The FDA approved Agios Pharmaceuticals Inc's (NASDAQ: AGIO) Pyrukynd (mitapivat) for hemolytic anemia in ad...
February 18, 2022, 5:41 am
Canada authorizes novavax's non-mrna covid vaccine for use in adults
Nuvaxovid, a protein-based Covid vaccine, could help reduce hesitancy among people suspicious of mRNA vaccine technology....
February 17, 2022, 1:07 pm
Canada authorizes novavax's non-mrna covid vaccine for use in adults
Nuvaxovid, a protein-based Covid vaccine, could help reduce hesitancy among people suspicious of mRNA vaccine technology....
February 17, 2022, 1:07 pm
Canada authorizes novavax's non-mrna covid vaccine for use in adults
Nuvaxovid, a protein-based Covid vaccine, could help reduce hesitancy among people suspicious of mRNA vaccine technology....
February 17, 2022, 1:07 pm
Global blood therapeutics' oxbryta scores european approval for sickle cell disease
The European Commission (EC) has approved Global Blood Therapeutics Inc's (NASDAQ: GBT) Oxbryta (voxelotor) for hemolytic anemia due to sickle cell...
February 16, 2022, 9:41 am
Global blood therapeutics' oxbryta scores european approval for sickle cell disease
The European Commission (EC) has approved Global Blood Therapeutics Inc's (NASDAQ: GBT) Oxbryta (voxelotor) for hemolytic anemia due to sickle cell...
February 16, 2022, 9:41 am
Global blood therapeutics' oxbryta scores european approval for sickle cell disease
The European Commission (EC) has approved Global Blood Therapeutics Inc's (NASDAQ: GBT) Oxbryta (voxelotor) for hemolytic anemia due to sickle cell...
February 16, 2022, 9:41 am